Author

Xi Li

Observed name: Li, Xi

Institution: Duality Biotherapeutics, Inc. (China)

Observed institution: Duality Biotherapeutics, Inc. (China)

ORCID: 0000-0002-1270-473X

Observed ORCID: 0000-0002-1270-473X

OpenAlex ID: A5092274079

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

2024 · Xi Li, Jun Yao, et al. · Journal of Translational Medicine · 20

DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer

2025 · Xi Li, Liwen Liang, et al. · Cancer Biology and Medicine · 6

Abstract 2655: DB-1323, a next-generation mesothelin targeting antibody-drug conjugate, demonstrated anti-tumor activity and favorable safety profile in pre-clinical models

2026 · Haiqing Hua, Xi Li, et al. · Cancer Research

Works count: 4

Citation count: 26

H-index: 2

I10-index: 1